1 completed, 1 terminated. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Terminated 1 |
| Phase 1 | 1 | Terminated 1 |
Follow Spinal Muscular Atrophy Type II: new trials by email Literature Review of Spinal Muscular Atrophy Type II trials Research Report on Spinal Muscular Atrophy Type II
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients. Olesoxime, Placebo - Spinal Muscular Atrophy Type II, Spinal Muscular Atrophy Type III Non Ambulant | Phase 2 | Completed | Hoffmann-La Roche | 165 | 2010-11-01 | 2016-11-22 |
| Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Types II or III sodium phenylbutyrate - Spinal Muscular Atrophy Type II, Spinal Muscular Atrophy Type III | Phase 1 / Phase 2 | Terminated | Westat | 9 | 2008-01-01 | 2010-09-08 |
Spinal Muscular Atrophies of Childhood (2) · Motor Neuron Disease (1) · Muscular Atrophy, Spinal (1)
Central Nervous System Diseases (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Heredodegenerative Disorders, Nervous System (2) · Nervous System Diseases (2) · Neurodegenerative Diseases (2) · Neuromuscular Diseases (2) · Spinal Cord Diseases (2) · Motor Neuron Disease (1) · Muscular Atrophy, Spinal (1)
4-phenylbutyric acid (1) · olesoxime (1)
Hoffmann-La Roche (1) · Westat (1)
Belgium (1) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · Poland (1) · United Kingdom (1) · United States (1)
Enrico Bertini, MD (1) · Peter R. Gilbert, ScM (1)
N01NS42361 (1)